TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03987022
Drug: Dilaudid Injectable Product
Normalized name: Dilaudid Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of narcotic for pain control postoperatively
Study: NCT03987022
Drug: Percocet 5Mg-325Mg Tablet
Normalized name: Percocet 5mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
Study: NCT02098629
Drug: Saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
Study: NCT00335816
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00335816
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01380028
Drug: oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
Study: NCT01380028
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02607800
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg tablet administered orally once daily with food
Study: NCT02607800
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg tablet administered orally once daily with or without food
Study: NCT02001103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Study: NCT04663308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules matched to study drug minus active substance
Study: NCT00492089
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00446420
Drug: Propofol, midazolam, fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
Study: NCT00516074
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, volume equivalent to active, twice a day
Study: NCT01589978
Drug: P2Y12 antagonist
Normalized name: Purinergic receptor subtype P2Y12 antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Study: NCT00278512
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Causes prevention of the cell division
Study: NCT00278512
Drug: Campath-1h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody against CD52 antigen
Study: NCT01480648
Drug: BI 144807 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that represents BI drug
Study: NCT02272478
Drug: Arm A Mylotarg plus DA Versus CPX-351
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
Study: NCT02189083
Drug: TSD
Normalized name: TSD Pt Cap-Red 33mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.
Study: NCT02272478
Drug: Arm D Small molecule or Not
Approvals — FDA: no, EMA: no, PMDA: no
Description: The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
Study: NCT03556371
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
Study: NCT03674008
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
Study: NCT02294071
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral liquid ibuprofen 10mg/kg (maximum 600 mg)
Study: NCT02294071
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral liquid acetaminophen 15mg/kg (max 975mg)
Study: NCT01903031
Drug: ATV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
Study: NCT01903031
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
Study: NCT04468607
Drug: BLYG8824A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLYG8824A will be administered at a flat dose independent of body weight.
Study: NCT03078400
Drug: SPL-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 150 mg administered either one time or two times per day.
Study: NCT01193270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water in volume equal to that of the comparator drug
Study: NCT00392080
Drug: CJ-023,423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg BID
Study: NCT00392080
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00392080
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen
Study: NCT00663910
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
Study: NCT02158975
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03000569
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
Study: NCT03112356
Drug: 99mTc-Leukoscan® scintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
Study: NCT03917628
Drug: SCT630
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT630 single s.c. injection
Study: NCT01226316
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
Study: NCT01226316
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
Study: NCT01226316
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
Study: NCT01226316
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
Study: NCT00601484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV, single dose
Study: NCT04136366
Drug: ADX-2191 (intravitreal methotrexate 0.8%)
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Study: NCT02669264
Drug: ADCT-402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT03850509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPS-2071-matched placebo, tablets, orally, BID.
Study: NCT05178355
Drug: KVD824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT05178355
Drug: Placebo to KVD824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04052867
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equivalent volume of normal saline is given
Study: NCT03948243
Drug: Caffeine 100 MG
Normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: probe substrate
Study: NCT03808337
Drug: Systemic Therapy/Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
Study: NCT04363697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02876094
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose-response
Study: NCT00957684
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily placebo comparator
Study: NCT01967173
Drug: Flovent Diskus® 100 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flovent is an ICS
Study: NCT01967173
Drug: Flovent Diskus® 250 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flovent is an ICS
Study: NCT01967173
Drug: Flovent Diskus® 500 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flovent is an ICS
Study: NCT01967173
Drug: Advair Diskus® 100/50 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advair is an ICS/LABA combination
Study: NCT01967173
Drug: Advair Diskus® 250/50 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advair is an ICS/LABA combination
Study: NCT02096679
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
Study: NCT03819465
Drug: MEDI5752
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI5752 IV Every 3 weeks (q3w)
Study: NCT03307785
Drug: TSR-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
Study: NCT03307785
Drug: TSR-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.
Study: NCT00546559
Drug: statins (simvastatin, pravastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03819465
Drug: AZD2936
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2936 IV
Study: NCT01046253
Drug: Prevacid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Delayed-Release Capsule
Study: NCT02739997
Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Study: NCT01101009
Drug: Perindopril + amlodipine + if necessary, hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Study: NCT01101009
Drug: olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Study: NCT00492531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
Study: NCT03382275
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: any oral or intravenous prescription iron supplement
Study: NCT03384745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains no active drug.
Study: NCT04050488
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Study: NCT04050488
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Study: NCT01824251
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05728632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsule, once daily, for 12 months
Study: NCT00579878
Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
Study: NCT01048333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Diskus and Placebo Turbuhaler
Study: NCT03008460
Drug: Eziclen®/Izinova®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution taken the evening before the colonoscopy
Study: NCT03008460
Drug: Klean-Prep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution taken the evening before the colonoscopy
Study: NCT00317954
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01182142
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,250 mg/m2 orally twice a day, days 1-14
Study: NCT01361568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. dose administered preoperatively
Study: NCT01361568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. dose administered postoperatively for pain
Study: NCT04786938
Drug: Saccharomyces Boulardii-Containing Product in Oral Dose Form
Normalized name: Saccharomyces boulardii-containing product in oral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
Study: NCT02197273
Drug: Standard of care analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04187105
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2
Study: NCT04187105
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
Study: NCT04187105
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
Study: NCT00365352
Drug: XP13512 600MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 600MG ONCE DAILY
Study: NCT00365352
Drug: XP13512 1200MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 1200MG ONCE DAILY
Study: NCT00365352
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO ONCE DAILY
Study: NCT02106975
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention
Study: NCT01272973
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral) administered once daily for 10 weeks.
Study: NCT02168127
Drug: Drug: PRC-063
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate Hydrochloride Extended-Release Capsules
Study: NCT02168127
Drug: PRC-063
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate Hydrochloride Extended-Release Capsules
Study: NCT01209052
Drug: GSK1325756
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
Study: NCT00611507
Drug: Oxaliplatin, 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
Study: NCT03617679
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
Study: NCT04187105
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
Study: NCT01357421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single iv dose of 0.9% sodium chloride for injection USP